, Tracking Stock Market Picks
Enter Symbol:
Soligenix, Inc. (SNGX) [hlAlert]

3 Months Gains
down 41.86 %

Soligenix, Inc. (SNGX) rated Buy with price target $3 by Maxim Group

Posted on: Tuesday,  Sep 24, 2013  8:25 AM ET by Maxim Group

Soligenix, Inc. (OTCBB: SNGX)
rated Buy with price target $3 by Maxim Group.

Soligenix, Inc., formerly DOR Biopharma, Inc., research and development biopharmaceutical company focused on developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases where there remains an unmet medical need; as well as several biodefense vaccines. The Company maintain two active business segments: BioTherapeutics and BioDefense. During the year ended December 31, 2008, the Company had two customers, the United States Federal Government and Orphan Australia Pty Ltd. (Orphan Australia), a specialty pharmaceutical company based in Melbourne, Australia. The Company?s biodefense business segment intends to convert its ricin toxin, botulinum toxin, and anthrax vaccine programs from early stage development to advanced development and manufacturing.

At Maxim Group, our vision for equity research is to be a client’s first call for value-added research on companies not widely followed by Wall Street. Maxim’s premier niche is emerging-growth companies in a variety of sectors, including healthcare, technology, retail and others. As strong believers in fundamental research, our analysts utilize a “bottom up” approach to making investment recommendations. We combine rigorous financial analysis of specific companies and industries with due diligence that includes frequent consults with suppliers, customers, competitors and senior management. By applying these skills and techniques, we are able to offer our clients differentiated research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/24/2013 8:25 AM Buy
2.15 3.00
as of 12/13/2013
1 Week   
1 Month   
3 Months   
1 YTD   

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy